| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg |
|
||
| 250mg | |||
| 500mg | |||
| Other Sizes |
| Targets |
Isoastragaloside I targets multiple signaling pathways. It inhibits Akt, NF-κB, MAPKs, and PI3K. It enhances the activity of hepatic FXR. It regulates the TGF-β/Smads signaling pathway. It upregulates antioxidant molecules downstream of Nrf2. It also possesses the activity of elevating adiponectin production, which may be mediated through these pathways.
|
|---|---|
| ln Vitro |
In vitro, Isoastragaloside I selectively increased adiponectin secretion in primary adipocytes without any obvious effects on a panel of other adipokines. It inhibits Akt, NF-κB, MAPKs, and PI3K pathways. It enhances the activity of hepatic FXR, regulates the TGF-β/Smads signaling pathway, and upregulates antioxidant molecules downstream of Nrf2. Quantitative IC50 values for its effects are not detailed in the publicly available sources.
|
| ln Vivo |
In vivo activity data for Isoastragaloside I is limited in publicly available literature. As a compound with anti-inflammatory and antioxidant properties in vitro, it is hypothesized to exhibit similar effects in vivo. Its ability to elevate adiponectin production suggests potential for in vivo studies on metabolic disorders. However, specific in vivo efficacy studies, including pharmacokinetic and pharmacodynamic parameters, have not been detailed in the available sources.
|
| Enzyme Assay |
For cell-free assays, the activity of Isoastragaloside I on Akt, NF-κB, MAPKs, and PI3K can be studied using kinase activity assays with purified enzymes. Its effect on FXR activity can be assessed using FXR reporter gene assays. Its antioxidant activity can be measured using DPPH or ABTS radical scavenging assays. Adiponectin production can be measured in cell-free systems by ELISA.
|
| Cell Assay |
For in vitro cellular assays, the adiponectin-elevating activity of Isoastragaloside I is assessed in primary adipocytes. Cells are treated with various concentrations of the compound, and adiponectin secretion into the culture medium is measured by ELISA. Its anti-inflammatory activity is assessed in LPS-stimulated macrophages by measuring cytokine production and signaling pathway activation.
|
| Animal Protocol |
For in vivo studies, Isoastragaloside I could be administered orally in animal models of metabolic disorders such as obesity or diabetes. Endpoints include serum adiponectin levels, glucose tolerance, insulin sensitivity, and inflammatory markers. Its antioxidant effects could be assessed by measuring oxidative stress markers in tissues.
|
| ADME/Pharmacokinetics |
Isoastragaloside I (CAS 84676-88-0) has a molecular formula of C45H72O16 and a molecular weight of 869.04 g/mol. It is also known as异黄芪皂苷I. Appearance: powder. Solubility: DMSO and other organic solvents. Storage: 2-8°C, protected from light. Purity: typically >98% for research use.
|
| Toxicity/Toxicokinetics |
No detailed toxicity data is publicly available. As a natural saponin from Astragalus membranaceus, it is generally considered to have low toxicity, but standard toxicological studies would be required for drug development. In vitro cytotoxicity assays in various cell lines are typically performed alongside efficacy studies to confirm that observed effects are not due to a general reduction in cell viability.
|
| References | |
| Additional Infomation |
Reports indicate that Astragalus membranaceus and Astragalus mongholicus contain isastragaloside I, and relevant data is available for reference.
Isoastragaloside I is a research-grade compound and is not approved for therapeutic use. It serves primarily as a pharmacological tool for studying adiponectin regulation, anti-inflammatory mechanisms, and antioxidant pathways. Its mechanism of action involves inhibition of Akt, NF-κB, MAPKs, and PI3K, enhancement of FXR activity, and upregulation of Nrf2-dependent antioxidant molecules. No clinical trials have been reported. |
| Molecular Formula |
C45H72O16
|
|---|---|
| Molecular Weight |
869.0436
|
| Exact Mass |
868.482
|
| CAS # |
84676-88-0
|
| PubChem CID |
60148697
|
| Appearance |
White to light brown solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
920.6±65.0 °C at 760 mmHg
|
| Flash Point |
264.7±27.8 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.596
|
| LogP |
2.03
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
16
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
61
|
| Complexity |
1690
|
| Defined Atom Stereocenter Count |
21
|
| SMILES |
CC(=O)O[C@@H]1CO[C@H]([C@@H]([C@H]1O)OC(=O)C)O[C@H]2CC[C@]34C[C@]35CC[C@@]6([C@H]([C@H](C[C@]6([C@@H]5C[C@@H]([C@H]4C2(C)C)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O)C)O)[C@]8(CC[C@H](O8)C(C)(C)O)C)C
|
| InChi Key |
HVPKALQHGQMJER-XOUPSZAESA-N
|
| InChi Code |
InChI=1S/C45H72O16/c1-21(47)56-26-19-55-38(34(31(26)51)57-22(2)48)60-28-11-13-45-20-44(45)15-14-41(7)35(43(9)12-10-29(61-43)40(5,6)54)23(49)17-42(41,8)27(44)16-24(36(45)39(28,3)4)58-37-33(53)32(52)30(50)25(18-46)59-37/h23-38,46,49-54H,10-20H2,1-9H3/t23-,24-,25+,26+,27-,28-,29-,30+,31-,32-,33+,34+,35-,36-,37+,38-,41+,42-,43+,44-,45+/m0/s1
|
| Chemical Name |
[(3R,4S,5R,6S)-5-acetyloxy-4-hydroxy-6-[[(1S,3R,6S,8R,9S,11S,12S,14S,15R,16R)-14-hydroxy-15-[(2R,5S)-5-(2-hydroxypropan-2-yl)-2-methyloxolan-2-yl]-7,7,12,16-tetramethyl-9-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-pentacyclo[9.7.0.01,3.03,8.012,16]octadecanyl]oxy]oxan-3-yl] acetate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~57.53 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.1507 mL | 5.7535 mL | 11.5070 mL | |
| 5 mM | 0.2301 mL | 1.1507 mL | 2.3014 mL | |
| 10 mM | 0.1151 mL | 0.5753 mL | 1.1507 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
